| C4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From Ongoing CFT1946 Phase 1 Trial in BRAF V600 Mutant Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024 | 09/13 10:00 | globenewswire.com |
| C4 Therapeutics to Present Preliminary CFT1946 Monotherapy Phase 1 Clinical Data at the European Society for Medical Oncology (ESMO) Congress 2024 | 09/08 18:05 | globenewswire.com |
| C4 Therapeutics Appoints Veteran Biotechnology Leader Stephen Fawell, Ph.D. to Board of Directors | 09/03 07:00 | globenewswire.com |
| C4 Therapeutics to Participate in Upcoming September Investor Conferences | 08/29 07:00 | globenewswire.com |
| C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Tops Revenue Estimates | 08/01 09:11 | zacks.com |
| C4 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights | 08/01 07:00 | globenewswire.com |
| C4 Therapeutics (CCCC) Soars 13.7%: Is Further Upside Left in the Stock? | 07/17 08:15 | zacks.com |
| C4 Therapeutics to Present Preliminary Monotherapy Data from the Ongoing Phase 1 Trial of CFT1946 as a Mini Oral Presentation at the ESMO Congress 2024 | 07/16 16:01 | globenewswire.com |
| C4 Therapeutics (CCCC) Upgraded to Buy: Here's Why | 07/09 13:01 | zacks.com |
| C4 Therapeutics to Participate in the Virtual UBS Targeted Protein Degradation Day | 07/08 07:00 | globenewswire.com |